Tuesday, February 07, 2012 7:02:13 PM
You have to understand that they way CGAQ is diluting shares is by
selling tens of millions of shares to so called "Investors" at a very
low "ridiculous price".
This are a special kind of investors. They do not invest to in order to see
the company grow. They invest to buy shares at the "low ridiculous price"
as admitted to by the CEO, and then sell at a low ask and they double their
money.
We were told in a recent press release (12/20/2011) that more shares
were going to be sold to this investors. They then have to wait six (6)
months from the date of purchase before they can sell.
According to my calculations we should see .000? by June of 2011 unless
something unexpected happens to change what it's in store for the P.P.S..
The investors like to buy shares and triple or at least double their money.
Since the present price now is about .0065, I would have to assume that
tens of millions of shares will be sold to them at approximately .0005.
I hope my calculations are wrong, unfortunately my previous comments
have been correct. Perhaps a Miracle will happen but if not then you can
expect that another 500 million shares may be added to the number of
shares in the market capitalization .
selling tens of millions of shares to so called "Investors" at a very
low "ridiculous price".
This are a special kind of investors. They do not invest to in order to see
the company grow. They invest to buy shares at the "low ridiculous price"
as admitted to by the CEO, and then sell at a low ask and they double their
money.
We were told in a recent press release (12/20/2011) that more shares
were going to be sold to this investors. They then have to wait six (6)
months from the date of purchase before they can sell.
According to my calculations we should see .000? by June of 2011 unless
something unexpected happens to change what it's in store for the P.P.S..
The investors like to buy shares and triple or at least double their money.
Since the present price now is about .0065, I would have to assume that
tens of millions of shares will be sold to them at approximately .0005.
I hope my calculations are wrong, unfortunately my previous comments
have been correct. Perhaps a Miracle will happen but if not then you can
expect that another 500 million shares may be added to the number of
shares in the market capitalization .
Recent BSEM News
- BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/31/2026 08:05:00 PM
- BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025 • GlobeNewswire Inc. • 03/30/2026 11:00:00 AM
- BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/24/2026 08:05:00 PM
- BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair • GlobeNewswire Inc. • 03/23/2026 03:40:56 PM
- BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair • GlobeNewswire Inc. • 03/23/2026 11:00:00 AM
- BioStem Technologies to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 24, 2026 • GlobeNewswire Inc. • 03/11/2026 08:05:00 PM
- BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference • GlobeNewswire Inc. • 02/20/2026 12:00:00 PM
- BioStem Technologies Highlights Alignment with FDA’s Openness to Bayesian Statistical Approaches in Clinical Research • GlobeNewswire Inc. • 02/03/2026 09:05:00 PM
- BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings’ Surgical and Wound Care Business • GlobeNewswire Inc. • 01/21/2026 10:30:00 PM
- BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes • GlobeNewswire Inc. • 01/07/2026 09:05:00 PM
- BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes • GlobeNewswire Inc. • 12/18/2025 12:00:00 PM
- BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference • GlobeNewswire Inc. • 12/10/2025 12:00:00 PM
- BioStem Technologies Expands Product Access in Medicaid • GlobeNewswire Inc. • 11/25/2025 01:59:13 PM
- BioStem Technologies Reports Third Quarter 2025 Financial Results • GlobeNewswire Inc. • 11/13/2025 09:02:00 PM
- BioStem Technologies Announces Filing of Restated Financial Statements • GlobeNewswire Inc. • 11/13/2025 09:01:00 PM
- BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes • GlobeNewswire Inc. • 11/05/2025 09:05:00 PM
- BioStem Technologies Secures Land Purchase at the Research Park at Florida Atlantic University in Boca Raton for Future Headquarters • GlobeNewswire Inc. • 11/05/2025 12:00:00 PM
- BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers • GlobeNewswire Inc. • 10/31/2025 11:00:00 AM
- BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025 • GlobeNewswire Inc. • 10/30/2025 08:05:00 PM
- BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant • GlobeNewswire Inc. • 10/27/2025 08:15:00 PM
- BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program • GlobeNewswire Inc. • 10/02/2025 04:00:00 PM
